Less than a tenth of individuals that would benefit from obesity jabs like Wegovy are able to get them, caution the World Health Organization as it releases its inaugural guidance on the medications.
Considering in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for increased and just access to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"Our latest guidance recognises that obesity is a long-term condition that can be treated with thorough and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key barriers to widespread access to the treatments that can assist patients in reducing substantial body mass, explains the organization.
Weight-Loss Drug Scarcity
Despite the present most optimistic scenario, the manufacturing of such drugs might only reach approximately 100 million people – under 10% of those who need them, according to the WHO.
The recommendation urges countries and companies to expand access, through approaches like patent sharing.
A patent on semaglutide – the primary ingredient of a leading brand – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Injections Function
These medications imitate a natural hormone to delay gastric emptying, curb appetite and increase feelings of fullness so people eat less.
Patients usually begin shedding pounds after several weeks of commencing the once-weekly jabs.
Studies suggests people may see weight return after a year of discontinuing the medication, because their usual appetite come back.
To be above a healthy weight raises your chance for experiencing health problems, such as type 2 diabetes, heart disease, brain attack, and specific cancers.
Excess weight concerns people in every country and was associated with millions of fatalities worldwide in 2024, as per the WHO.
